biostudies-literatureLee SYAlzheimer's Association ResearchNew Vision Research Charleston Conference on Alzheimer's DiseaseNIA)Larry L. Hillblom FoundationNIH)e70626https://www.ebi.ac.uk/biostudies/studies/S-EPMC12412752biostudies-literatureUnknown21(9)<h4>Introduction</h4>Glial fibrillary acidic protein (GFAP) may contribute to Alzheimer's pathology at early disease stages. GFAP moderation of Alzheimer's disease (AD)-related neurodegeneration and cognition is unclear.<h4>Methods</h4>We examined plasma GFAP moderation of AD biomarkers (amyloid beta [Aβ]-positron emission tomography [PET][A]; plasma phosphorylated tau-181 [p-tau181][T₁]), neurodegeneration (plasma NfL[N_plasma]; structural magnetic resonance imaging [MRI][N_MRI]), and cognition (Cog_memory; Cog_executive) in two cohorts: University of California San Francisco (UCSF) (N = 212, 91.0% non-Hispanic/Latino White [NHLW], age = 74.7 [7.6] years, 75.9% cognitively unimpaired [CU]) and 1Florida Alzheimer's Disease Research CentersAlzheimer's & dementia : the journal of the Alzheimer's AssociationModerating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.PMC12412752UF1NS100608R01AG032289R01AG072475K23AG0848832024‐A‐001‐CTR2024-A-001-CTRAARF-22-974065AARG-20-683875P30AG066506P30AG062422K23AG0735142024-001-12018-A-006-NETR01AG0456112018‐A‐006‐NETK23AG058752R01AG048234AARF-23-1145318Casaletto KBEmanuel OMDeKosky STMatusz EFLoewenstein DARosselli MBarker WWRundek TMarsiske MLago ALVaillancourt DEDiaz VEAsken BMDeSimone JLa Joie RRabinovici GDArmstrong MJArias FRayaprolu SStaffaroni AVandeVrede LCuriel Cid REWebb JWang WEPaolillo EWDuara RVelez-Uribe IKramer JHChan BSmith GELee SYSaloner RWiens BASanderson-Cimino MRojas JCLevy SAfalseModerating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.<h4>Introduction</h4>Glial fibrillary acidic protein (GFAP) may contribute to Alzheimer's pathology at early disease stages. GFAP moderation of Alzheimer's disease (AD)-related neurodegeneration and cognition is unclear.<h4>Methods</h4>We examined plasma GFAP moderation of AD biomarkers (amyloid beta [Aβ]-positron emission tomography [PET][A]; plasma phosphorylated tau-181 [p-tau181][T₁]), neurodegeneration (plasma NfL[N_plasma]; structural magnetic resonance imaging [MRI][N_MRI]), and cognition (Cog_memory; Cog_executive) in two cohorts: University of California San Francisco (UCSF) (N = 212, 91.0% non-Hispanic/Latino White [NHLW], age = 74.7 [7.6] years, 75.9% cognitively unimpaired [CU]) and 1Florida Alzheimer's Disease Research Centers2025-01-01T00:00:00Z2025 Sep2026-05-29T22:39:01.75Z2026-04-08T06:18:57.863ZS-EPMC124127524091172110.1002/alz.70626